AAO 2020: Study confirms Phase III results for uveitis treatment

Video
Conference|AAO

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Related Videos
Related Content

ProQR Therapeutics offers update on sale of ophthalmic assets

September 29th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

What to expect from virtual AAO 2020

November 5th 2020

World Retina Day: New data from Kiora Pharmaceuticals shines a light on inherited retinal diseases

September 25th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 25th 2023

ProQR Therapeutics offers update on sale of ophthalmic assets

September 29th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

What to expect from virtual AAO 2020

November 5th 2020

World Retina Day: New data from Kiora Pharmaceuticals shines a light on inherited retinal diseases

September 25th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 25th 2023

ProQR Therapeutics offers update on sale of ophthalmic assets

September 29th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

What to expect from virtual AAO 2020

November 5th 2020

World Retina Day: New data from Kiora Pharmaceuticals shines a light on inherited retinal diseases

September 25th 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 25th 2023
© 2023 MJH Life Sciences

All rights reserved.